Estimaciones de analistas de Wall Street para Cumberland Pharmaceuticals Inc. (CPIX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.13 | ||
| 2026-08-04 | $-0.20 | $-0.13 | -53.8% |
| 2026-05-05 | $-0.13 | $-0.13 | +0.0% |
| 2026-03-03 | $-0.01 | $-0.13 | +92.3% |
| 2025-11-04 | $-0.06 | $-0.13 | +53.8% |
| 2025-08-05 | $0.02 | ||
| 2025-05-06 | $0.16 | $-0.01 | +1700.0% |
| 2025-03-04 | $-0.02 | $-0.11 | +81.8% |
Ratios de valoración
| Precio / Valor contable | 6.05 |
| EV / EBITDA | -17.72 |
| Rentabilidad por dividendo | 21.30% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $33.0M | $41.2M | $40.7M | $34.4M | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Coste de Ventas | $6.0M | $7.4M | $7.4M | $7.4M | $8.7M | $8.8M | $9.1M | $6.1M | $6.6M | $6.7M |
| Beneficio Bruto | $27.1M | $33.8M | $33.4M | $27.0M | $28.8M | $27.2M | $32.9M | $33.5M | $31.3M | $37.9M |
| I+D | $3.2M | $3.9M | $7.3M | $6.9M | $5.8M | $5.7M | $6.7M | $5.8M | $4.8M | $5.6M |
| Generales y Administrativos | $23.1M | $31.5M | $30.7M | $25.3M | $25.0M | $24.8M | $26.8M | $29.1M | $28.1M | $31.0M |
| Gastos Operativos | $28.5M | $37.9M | $40.8M | $36.3M | $35.2M | $34.9M | $38.6M | $43.0M | $37.7M | $40.6M |
| Beneficio Operativo | -$1.4M | -$4.1M | -$7.4M | -$9.3M | -$6.4M | -$7.7M | -$5.7M | -$9.6M | -$6.4M | -$2.8M |
| EBITDA | $1.2M | -$1.1M | -$8.2M | -$4.6M | -$1.6M | -$857833 | $332919 | $2.5M | $182422 | $3.0M |
| Gastos por Intereses | $106392 | $92904 | $195848 | $246186 | $263627 | $98031 | $585995 | $667861 | $605508 | $495990 |
| Beneficio Antes de Impuestos | -$1.3M | -$3.9M | -$7.0M | -$9.3M | -$6.6M | -$5.6M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| Impuestos | -$330924 | $4.2M | $16636 | -$79316 | $55902 | $34891 | $68850 | $45769 | -$22669 | $40256 |
| Beneficio Neto | -$944683 | -$8.0M | -$7.0M | -$3.5M | -$3.3M | -$3.5M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| BPA | $-0.06 | $-0.50 | $-0.45 | $-0.23 | $-0.22 | $-0.24 | $-0.38 | $-0.44 | $-0.46 | $-0.19 |
| BPA Diluido | $-0.06 | $-0.50 | $-0.45 | $-0.23 | $-0.22 | $-0.24 | $-0.38 | $-0.44 | $-0.46 | $-0.19 |
| Acciones en Circulación (Diluidas) | $16.2M | $15.9M | $15.6M | $15.4M | $15.2M | $14.9M | $14.6M | $14.3M | $14.1M | $15.0M |
Precio
| Precio | $6.98 |
| Capitalización | $105M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABVC · CALC · CELU · DYAI · LTRN · LVTX · NOTV
Explorar sector: Healthcare · Drug Manufacturers - Specialty & Generic
Más secciones de CPIX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones